世界のがんワクチン市場及び開発パイプライン...市場調査レポートについてご紹介

1. Introduction to Cancer Vaccines

2. Cancer Vaccines: Mechanism & Innovations
2.1 Idiotype Cancer Vaccine Mechanism
2.2 Cellular Cancer Vaccines Mechanism
2.3 Ganglioside Antigens based Cancer Vaccines Mechanism
2.4 Peptide Cancer Vaccine Mechanism
2.5 Tumor Host Interaction Cancer Vaccine Mechanism

3. Adjuvants Platforms for Cancer Vaccines Delivery

4. Global Cancer Vaccines Market Overview
4.1 Current Market Scenario
4.2 Clinical Pipeline Overview

5. Personalized Cancer Vaccines: Progress & Possibilities

6. Public HPV Cancer Vaccination Program

7. Global Cancer Vaccines Market Dynamics
7.1 Favorable Market Parameters
7.1.1 Increasing Demand for Cancer Vaccines
7.1.2 Government Funding & Support
7.1.3 Innovative Technologies for Cancer Vaccine Development
7.1.4 On Demand Personalized Cancer Vaccines
7.1.5 Myriad of Demographs for Cancer Vaccine Development
7.2 Issues to be Resolved

8. Future Prospects of Cancer Vaccines

9. Global Cancer Vaccines Clinical Pipeline Insight by Phase, Indication, Company & Country
9.1 Phase: Unknown
9.2 Phase: Research
9.3 Phase: Preclinical
9.4 Phase: Clinical
9.5 Phase-I
9.6 Phase-I/II
9.7 Phase-II
9.8 Phase-II/III
9.9 Phase-III
9.10 Phase: Preregistration
9.11 Phase: Registered

10. Marketed Cancer Vaccines Clinical Insight by Indication, Company & Country

11. Suspended & Discontinued Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country
11.1 No Development Reported
11.2 Discontinued
11.3 Suspended

12. FDA Regulatory Framework for Cancer Vaccines Development & Marketing
12.1 Considerations for both Early and Late Phase Clinical Trials
12.1.1 Patient Population
12.1.2 Monitoring the Immune Response
12.1.3 Biomarkers as Evidence of Efficacy
12.1.4 Adjuvants Used To Stimulate Immune Response
12.1.5 Multi-Antigen Vaccines
12.1.6 Disease Progression/Recurrence Immediately or Shortly After The Initial Administration Of Cancer Vaccines
12.1.7 Concomitant & Subsequent Therapies
12.2 Considerations for Early Phase Clinical Trials
12.2.1 Starting Dose & Dosing Schedule
12.2.2 Booster & Maintenance Therapy
12.2.3 Dose Escalation
12.2.4 Single Arm Versus Randomized Phase 2 Trials In Early Development
12.3 Considerations for Late Phase Clinical Trials
12.3.1 Safety Profile from Early Phase Clinical Trials
12.3.2 Endpoints
12.3.3 Statistical Issues
12.3.4 Control Issues
12.3.5 Delayed Vaccine Effect
12.3.6 Autologous Vaccine Trials
12.3.7 Accelerated Approval Regulations

13. Competitive Landscape: Business Overview & Product Pipeline
13.1 Advaxis
13.2 Celldex Therapeutics
13.3 Dendreon Corporation
13.4 Galena Biopharma
13.5 ImmunoCellular Therapeutics
13.6 ImmunoGen
13.7 Inovio Pharmaceuticals
13.8 Merck
13.9 NeoStem Oncology
13.10 NewLink Genetics
13.11 Northwest Biotherapeutics
13.12 Novartis
13.13 Peregrine Pharmaceuticals
13.14 Roche
13.15 Seattle Genetics

Figure 1-1: Categorization & Function of Cancer Vaccines
Figure 2-1: Classification of Different Types of Cancer vaccines

Figure 4-1: Global Cancer Vaccines Market (US$ Billion), 2014-2020
Figure 4-2: Global Cancer Vaccines Market by Region (%), 2014 & 2020
Figure 4-3: Examples of Commercially Available Cancer Vaccines

Figure 4-4: Global Cancer Vaccines Clinical Pipeline by Phase (%), 2014
Figure 4-5: Global Cancer Vaccines Clinical Pipeline by Phase (Number), 2014
Figure 4-6: No Development Reported in Cancer Vaccines Pipeline by Phase (%), 2014
Figure 4-7: No Development Reported in Cancer Vaccines Pipeline by Phase (Number), 2014
Figure 4-8: Discontinued Cancer Vaccines in Pipeline by Phase (%), 2014
Figure 4-9: Discontinued Cancer Vaccines in Pipeline by Phase (Number), 2014
Figure 4-10: Suspended Cancer Vaccines in Pipeline by Phase (%), 2014
Figure 4-11: Suspended Cancer Vaccines in Pipeline by Phase (Number), 2014

Figure 5-1: Overview of Personalized Cancer Vaccines Development
Figure 5-2: Methodology for the Development of Personalized Cancer Vaccine
Figure 5-3: Schematic Representation of Development of Skin Implant for Cancer Vaccine
Figure 6-1: Prophylactic Cancer Vaccines Available for Different Serotypes of HPV
Figure 7-1: Factors Responsible for High Demand of Cancer Vaccines

Figure 13-1: Advaxis Clinical Pipeline
Figure 13-2: Celldex Therapeutics Clinical Pipeline
Figure 13-3: Galena Biopharma Clinical Pipeline
Figure 13-4: ImmunoCellular Therapeutics Clinical Pipeline
Figure 13-5: ImmunoGen Clinical Pipeline
Figure 13-6: Inovio Pharmaceuticals Clinical Pipeline
Figure 13-7: NewLink Genetics Corporation Clinical Pipeline
Figure 13-8: Northwest Biotherapeutics Clinical Pipeline
Figure 13-9: Peregrine Pharmaceuticals Clinical Pipeline
Figure 13-10: Seattle Genetics Clinical Pipeline

Table 5-1: Different Types of Biomarkers for Personalized Cancer Vaccine Development